Albekairi Thamer H, Alshammari Abdulrahman, Alharbi Metab, Alshammary Amal F, Tahir Ul Qamar Muhammad, Anwar Tasneem, Ismail Saba, Shaker Bilal, Ahmad Sajjad
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia.
Vaccines (Basel). 2022 Apr 28;10(5):691. doi: 10.3390/vaccines10050691.
Whipple's disease is caused by , a Gram-positive pathogenic bacterium. It is considered a persistent infection affecting various organs, more likely to infect males. There is currently no licensed vaccination available for Whipple's disease; thus, the development of a chimeric peptide-based vaccine against has the potential to be tremendously beneficial in preventing Whipple's disease in the future. The present study aimed to apply modern computational approaches to generate a multi-epitope-based vaccine that expresses antigenic determinants prioritized from the core proteome of two whole proteomes. Using an integrated computational approach, four immunodominant epitopes were found from two extracellular proteins. Combined, these epitopes covered 89.03% of the global population. The shortlisted epitopes exhibited a strong binding affinity for the B- and T-cell reference set of alleles, high antigenicity score, nonallergenic nature, high solubility, nontoxicity, and excellent binders of DRB1*0101. Through the use of appropriate linkers and adjuvation with a suitable adjuvant molecule, the epitopes were designed into a chimeric vaccine. An adjuvant was linked to the connected epitopes to boost immunogenicity and efficiently engage both innate and adaptive immunity. The physiochemical properties of the vaccine were observed favorable, leading toward the 3D modeling of the construct. Furthermore, the vaccine's binding confirmation to the TLR-4 critical innate immune receptor was also determined using molecular docking and molecular dynamics (MD) simulations, which shows that the vaccine has a strong binding affinity for TLR4 (-29.4452 kcal/mol in MM-GBSA and -42.3229 kcal/mol in MM-PBSA). Overall, the vaccine described here has a promising potential for eliciting protective and targeted immunogenicity, subject to further experimental testing.
惠普尔病由一种革兰氏阳性致病细菌引起。它被认为是一种影响多个器官的持续性感染,男性更易感染。目前尚无针对惠普尔病的获批疫苗;因此,开发一种基于嵌合肽的抗该细菌疫苗未来有可能对预防惠普尔病极为有益。本研究旨在应用现代计算方法来生成一种基于多表位的疫苗,该疫苗表达从两种该细菌全蛋白质组的核心蛋白质组中优先筛选出的抗原决定簇。使用综合计算方法,从两种细胞外蛋白中发现了四个免疫显性表位。这些表位组合起来覆盖了全球89.03%的人群。入围的表位对B细胞和T细胞等位基因参考集表现出很强的结合亲和力、高抗原性评分、无过敏性质、高溶解性、无毒性,并且是DRB1*0101的优秀结合物。通过使用合适的连接子并与合适的佐剂分子进行佐剂化,将这些表位设计成一种嵌合疫苗。一种佐剂与连接后的表位相连,以增强免疫原性并有效激活固有免疫和适应性免疫。观察到该疫苗的理化性质良好,从而对构建体进行了三维建模。此外,还使用分子对接和分子动力学(MD)模拟确定了该疫苗与TLR - 4关键固有免疫受体的结合确认情况,结果表明该疫苗对TLR4具有很强的结合亲和力(MM - GBSA中为 - 29.4452千卡/摩尔,MM - PBSA中为 - 42.3229千卡/摩尔)。总体而言,本文所述疫苗在引发保护性和靶向免疫原性方面具有广阔前景,但有待进一步的实验测试。